ABSTRACT
Artemisinin–naphthoquine (ART–NQ) is an oral, co-formulated antimalarial therapy that was developed by the Academy of Military Medical Sciences in China in the 1980s. It is now marketed as ARCO (Kunming Pharmaceutical Company, China), a single-dose treatment for uncomplicated malaria (Anthony et al., 2012). Although it has not received endorsement from the World Health Organization (WHO) or other pharmacoregulatory body (Wells and Poll, 2010), it is registered in more than 10 countries, and an estimated 1 million patients receive ARCO annually (Wells and Poll, 2010).
